Treatment of cervical intraepithelial neoplasia with topical imiquimod: A randomized controlled trial

Obstetrics and Gynecology

Volumn 120, Issue 1, 2012, Pages 152-159

  Grimm, Christoph ^a   Polterauer, Stephan ^a   Natter, Camilla ^a   Rahhal, Jasmin ^a   Hefler, Lukas ^b   Tempfer, Clemens B ^b   Heinze, Georg ^b   Stary, Georg ^b   Reinthaller, Alexander ^b   Speiser, Paul ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; IMIQUIMOD;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; PAPILLOMAVIRUS INFECTION; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS LOAD;

ADULT; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; REMISSION INDUCTION; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD; YOUNG ADULT;

EID: 84871710213     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31825bc6e8     Document Type: Article

References (25)

1. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958-64.
2. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008;9:425-34.
3. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24(suppl 3):11-25.
4. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50.
5. Martin-Hirsch PP, Paraskevaidis E, Bryant A, Dickinson HO, Keep SL. Surgery for cervical intraepithelial neoplasia. The Cochrane Database of Systematic Reviews 2010m Ussye 6. Art. No.: CD001318. DOI: 10.1002/14651858.CD001318.pub2.
6. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D, et al. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol 2007;197:340-5.
7. Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008;337:a1284.
8. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006;367:489-98.
9. Foley G, Alston R, Geraci M, Brabin L, Kitchener H, Birch J. Increasing rates of cervical cancer in young women in England: an analysis of national data 1982-2006. Br J Cancer 2011;105:177-84.
10. Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol 2004;191:105-13.
11. Kietpeerakool C, Srisomboon J. Medical treatment of cervical intraepithelial neoplasia II, III: an update review. Int J Clin Oncol 2009;14:37-42.
12. van Seters M, van Beurden M, ten Kate FJ, Beckmann I, Ewing PC, Eijkemans MJ, et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med 2008;358:1465-73.
13. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 2007;204:1441-51.
14. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81.
15. Terlou A, van Seters M, Kleinjan A, Heijmans-Antonissen C, Santegoets LA, Beckmann I, et al. Imiquimod-induced clearance of HPV is associated with normalization of immune cell counts in usual type vulvar intraepithelial neoplasia. Int J Cancer 2010;127:2831-40.
16. Hefler LA, Grimm C, Speiser P, Sliutz G, Reinthaller A. The cyclooxygenase-2 inhibitor rofecoxib (Vioxx) in the treatment of cervical dysplasia grade II-III. A phase II trial. Eur J Obstet Gynecol Reprod Biol 2006;125:251-4.
17. Pachman DR, Barton DL, Clayton AC, McGovern RM, Jefferies JA, Novotny PJ, et al. Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia. Am J Obstet Gynecol 2012;206:42.e1-7.
18. Ferenczy A, Choukroun D, Arseneau J. Loop electrosurgical excision procedure for squamous intraepithelial lesions of the cervix: advantages and potential pitfalls. Obstet Gynecol 1996;87:332-7.
19. Fine BA, Feinstein GI, Sabella V. The pre- and postoperative value of endocervical curettage in the detection of cervical intraepithelial neoplasia and invasive cervical cancer. Gynecol Oncol 1998;71:46-9.
20. Veridiano NP, Delke I, Tancer ML. Accuracy of colposcopically directed biopsy in patients with cervical neoplasia. Obstet Gynecol 1981;58:185-7.
21. Moscicki AB, Ma Y, Wibbelsman C, Darragh TM, Powers A, Farhat S, et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol 2010;116:1373-80.
22. Bulkmans NW, Berkhof J, Bulk S, Bleeker MC, van Kemenade FJ, Rozendaal L, et al.; POBASCAM Study Group. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 2007;96:1419-24.
23. Castle PE, Schiffman M, Wheeler CM, Wentzensen N, Gravitt PE. Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3. Cancer Epidemiol Biomarkers Prev 2010;19:1675-81.
24. Bodner K, Bodner-Adler B, Wierrani F, Kubin A, Szölts-Szölts J, Spängler B, et al. Cold-knife conization versus photodynamic therapy with topical 5-aminolevulinic acid (5-ALA) in cervical intraepithelial neoplasia (CIN) II with associated human papillomavirus infection: a comparison of preliminary results. Anticancer Res 2003;23:1785-8.
25. Ruffin MT, Bailey JM, Normolle DP, Michael CW, Bieniasz ME, Kmak DC, et al. Low-dose topical delivery of all-trans retinoic acid for cervical intraepithelial neoplasia II and III. Cancer Epidemiol Biomarkers Prev 2004;13:2148-52.